[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 995
Citations 0
Research Letter
January 21, 2020

Analysis of Pharmaceutical Industry Marketing of Stimulants, 2014 Through 2018

Author Affiliations
  • 1Grayken Center for Addiction and Department of Pediatrics, Boston Medical Center, Boston, Massachusetts
  • 2Division of General Pediatrics, Department of Pediatrics, Boston University School of Medicine, Boston, Massachusetts
  • 3Department of Pediatrics, Boston Medical Center, Boston, Massachusetts
  • 4Center for Opioid Epidemiology & Policy, Department of Population Health, New York University School of Medicine, New York
  • 5Department of Health Law, Policy, and Management, Boston University School of Public Health, Boston, Massachusetts
  • 6Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island
  • 7Division of General Internal Medicine, University of California, San Francisco, San Francisco
JAMA Pediatr. 2020;174(4):385-387. doi:10.1001/jamapediatrics.2019.5526

Use of prescription stimulants doubled from 2006 to 2016 in the United States1 and, as of 2013, it resulted in more pharmaceutical expenditures for children than any other medication class.2 Although the rise in stimulant use parallels increasing attention-deficit/hyperactivity disorder diagnosis rates, stimulants, even when appropriately prescribed, are commonly diverted and used nonmedically.3 It is important to consider factors that may contribute to a potential oversupply of stimulants. Pharmaceutical company marketing is associated with increased prescribing.4 The extent to which physicians receive marketing for stimulants is not well described.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words